Pipeline update on lead solid tumour programme, BVX002

November 30th, 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

BIVICTRIX THERAPEUTICS PLC
(“BiVictriX” or the “Company”)

 

Pipeline update on lead solid tumour programme, BVX002

 

            • Emerging data identifies ovarian cancer as one of the lead indications for BVX002, BiVictriX’s first-in-class Antibody Drug Conjugate (ADC) targeting solid tumour indications
            • Final antibody sequences selected for BVX002 drug candidate, Company on track to identify development lead in 2024
            • An updated version of BiVictriX’s corporate presentation is now available on the Company’s website

 

Alderley Park, 30 November 2023 – BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a differentiated approach to develop novel, next-generation anti-cancer precision Antibody Drug Conjugates, offering substantially improved cancer cell selectivity and therapeutic activity, announces that the final sequences have been selected for the Company’s second programme, BVX002, targeting solid tumour indications, with a lead indication in ovarian cancer.

These final antibody sequences, selected from the panel identified earlier this year, showed strong efficacy and selectivity towards targeted cancer cells as compared to non-target cells and passed early assessments of developability.

In addition, emerging data from primary patient samples using a combination of next generation sequencing techniques and laboratory-based profiling has generated initial results which suggest that the antigen fingerprint targeted by BVX002 is present in multiple solid tumour indications, with especially high prevalence in high-grade serous ovarian cancer (expressed in >86% of ovarian cancer patient samples), representing a disease of significant unmet need and commercial potential for BVX002.

Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc, said: “ADCs have demonstrated incredible promise as an alternative therapeutic option to current monotherapies and combination therapies across difficult-to-treat cancers, backed by high specificity, versatility and selectivity. We have been encouraged by BiVictriX’s progress to date in our lead BVX001 programme for the treatment of Acute Myeloid Leukaemia and are also pleased by the further development and expansion of our proprietary ADC pipeline, where BVX002 is showing early promise in targeting high-grade serous ovarian carcinoma, which accounts for 75% of epithelial ovarian cancers. We expect to identify a lead development candidate for BVX002 in 2024 and look forward to providing our shareholders with further updates as appropriate.”

Corporate Presentation

An updated version of BiVictriX’s corporate presentation reflecting the recent progress made across the BVX001 and BVX002 programmes, as well as the Company’s strengthened IP position, is now available on the Company’s website.

ENDS

 

For more information, please contact:

BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Michael Kauffman, Non‐Executive Chairman                            Email: info@bivictrix.com

SP Angel Corporate Finance LLP (NOMAD and Broker)     Tel: +44 (0) 20 3470 0470
David Hignell, Kasia Brzozowska (Corporate Finance)
Vadim Alexandre, Rob Rees (Sales and Broking)

Panmure Gordon (UK) Limited (Joint Broker)                        Tel: +44 (0) 20 7886 2500
Rupert Dearden/Freddy Crossley/Emma Earl

ICR Consillium
Mary-Jane Elliott, Namrata Taak, Max Bennett,                     Tel: +44 (0) 20 3709 5700
Emmalee Hoppe                                                                        Email: bivictrix@consilium-comms.com

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or “Bi-Cygni® fingerprints”, on tumour cells, which are largely absent from healthy cells.

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company’s novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com.